Heterologous expression of hydroxylase coupled with pathway optimization enables highly efficient ʟ-DOPA production...

ʟ-3,4-dihydroxyphenylalanine (ʟ-DOPA), the direct precursor of the neurotransmitter dopamine, is a cornerstone therapeutic agent for Parkinson's disease. In this study, Corynebacterium glutamicum was used as a microbial chassis to systematically evaluate its potential as a cell factory for ʟ-DOPA production. The strain was initially evaluated for ʟ-DOPA tolerance to confirm its suitability for production. Key hydroxylases, HpaB and HpaC, were introduced, and promoter and ribosome-binding site (RBS) optimization was applied to establish a de novo ʟ-DOPA biosynthetic pathway. To minimize flux toward competing branches, enzymes encoded by pheA and trpE2 were deleted, and fermentation conditions were optimized to balance cell growth with product formation. Promoter engineering was further employed to enhance the expression of Cgl0226, Cgl0218, and Cgl2101, thereby increasing the availability of the precursor ʟ-tyrosine for ʟ-DOPA biosynthesis. Additionally, deletion of competing shikimate pathway enzymes (encoded by qsuB and qsuD) combined with enhanced expression of aroA and aroC elevated carbon flux through the shikimate pathway. The final engineered strain, KD20, achieved an ʟ-DOPA titer of 710.9 ± 13.2 mg/L in shake-flask fermentation. Upon scale-up to a 5 L bioreactor under optimized conditions, the final titer reached 4605.58 ± 21.73 mg/L, representing the highest ʟ-DOPA yield reported in C. glutamicum. These results highlight the robust production capacity of C. glutamicum and underscore its strong potential for ʟ-DOPA biosynthesis.